SKL-2841(SKL-2841) - 药物靶点：CCL2 x CCL4_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

CCL2 x CCL4

作用机制

CCL2抑制剂(C-C基序趋化因子-2抑制剂)、CCL4 inhibitors(趋化因子CCL4抑制剂)

治疗领域

皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

系统性硬皮病

原研机构

Kyoto Prefectural University of Medicine

在研机构-

非在研机构

Kyoto Prefectural University of Medicine

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 SKL-2841 相关的临床结果

登录后查看更多信息

100 项与 SKL-2841 相关的转化医学

登录后查看更多信息

100 项与 SKL-2841 相关的专利（医药）

登录后查看更多信息

1

项与 SKL-2841 相关的文献（医药）

2007-05-01·Biomedicine & Pharmacotherapy2区 · 医学

SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice

2区 · 医学

Article

作者: Yasunori Tsubouchi ; Takashi Nakamura ; Masayuki Okamoto ; Hirahito Endo ; Masataka Kohno ; Makoto Wada ; Toshikazu Yoshikawa ; Aihiro Yamamoto ; Masahide Hamaguchi ; Atsushi Omoto ; Yutaka Kawahito ; Hidetaka Ishino ; Yukiharu Matsumoto ; Mizuho Kimura

Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis and excessive collagen deposition in the skin and various internal organs. In early stages of SSc, the dermis reveals infiltration of inflammatory cells associated with increased collagen synthesis. SKL-2841 was initially synthesized as a novel small molecule antagonist of MCP-1. In this study, we indicated that SKL-2841 also exerts anti-chemotactic activity for MIP-1 beta in mouse spleen cells. In the early stages of bleomycin-induced skin lesions, immunohistochemical analysis showed the expression of both MCP-1 and MIP-1 beta in dermal inflammatory cells. Moreover, intraperitoneal administration of SKL-2841 suppressed the infiltration of inflammatory mononuclear cells and polymorphonuclear cells in the acute phase and also significantly suppressed fibrillization in the chronic phase in bleomycin-induced scleroderma, compared with PBS treatment. These findings suggest that SKL-2841 has potential as a compound for the treatment of conditions associated with skin fibrosis such as SSc.

100 项与 SKL-2841 相关的药物交易

登录后查看更多信息